Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
Personalis, the National Cancer Center, and Ono Pharmaceutical today announced they have entered into a […]
Malaysian Genomics Inks Expansion Agreement in Bangladesh
Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced a strategic […]
SynAct Pharma Appoints Björn Westberg as Chief Financial Officer (CFO)
SynAct Pharma has announced that Björn Westberg has been appointed Chief Financial Officer (CFO) and […]
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]
Eikonoklastes Announces Formation of Scientific Advisory Board
Eikonoklastes Therapeutics, a biopharmaceutical company developing a novel gene therapy platform to discover and develop […]
SonoThera™ Announces Research Collaboration with Janssen Pharmaceuticals to Accelerate Development of Ultrasound-Guided Nonviral Gene Therapy Platform
SonoThera, a biotechnology company dedicated to treating the root cause of human diseases through genetic […]
CHARM Therapeutics Receives Investment for Deep Learning-Enabled Drug Discovery Research from NVIDIA
CHARM Therapeutics, a 3D deep-learning biotechnology company discovering and developing transformational medicines, today announced an […]
Dwaine Vance, Randox, on Molecular Diagnostics
At ECCMID, we caught up with Dwaine Vance from Randox, who discusses his company’s contribution […]
Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases
Nido Biosciences, a clinical-stage company developing precision treatments for debilitating neurological diseases, emerged from stealth […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more